Naka et al. has already combined LY364947-mediated TGF-β inhibition with TKI treatment and found that CML was eradicated in the CML mouse model 16 and Hurtz et al. inactivated BCL6 using a retro-inverso BCL6 peptide inhibitor, resulting in delayed progression of CML when combined with TKIs 18. The gene discussed is BCL6; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.